Biswas Joyanta, Ali Sk Asif, Malik Samaresh, Nag Subhadeep, Mukherjee Piyali, Saha Abhik
Institute of Health Sciences, Presidency University, Kolkata, West Bengal, India.
PLoS Pathog. 2025 Aug 7;21(8):e1013410. doi: 10.1371/journal.ppat.1013410. eCollection 2025 Aug.
Epstein-Barr virus (EBV) establishes life-long persistence infection displaying a biphasic viral life cycle - latent phase and lytic replication. While latent EBV infection is linked to several B- and epithelial cell malignancies, periodic lytic-cycle reactivation is crucial for maintaining viral progeny and transmission. Targeting lytic reactivation offers a promising therapeutic avenue for EBV-associated cancers. Our genome-wide transcriptomic analysis reveals that E2F1 is transcriptionally activated during EBV latency but significantly suppressed during lytic reactivation. While ectopic E2F1 expression suppresses lytic replication, E2F1 depletion markedly accelerates this process. Mechanistically, we establish that E2F1 and the lytic transactivator BZLF1 form a negative transcriptional feedback loop, tightly controlling viral lytic replication. Furthermore, E2F1 positively regulates c-Myc expression and together they repress leaky BZLF1 expression during latency. Notably, c-Myc does not influence E2F1 expression, nor does BZLF1 modulate c-Myc transcription, underlining a distinct regulatory hierarchy. In sum, our findings reveal that EBV tightly controls the latent-to-lytic switch through precise regulation of E2F1 expression, positioning E2F1 as a pivotal regulator of both cellular and viral gene expression.
爱泼斯坦-巴尔病毒(EBV)建立终身持续性感染,呈现双相病毒生命周期——潜伏期和裂解复制期。虽然潜伏性EBV感染与多种B细胞和上皮细胞恶性肿瘤有关,但周期性的裂解周期重新激活对于维持病毒后代和传播至关重要。靶向裂解重新激活为EBV相关癌症提供了一条有前景的治疗途径。我们的全基因组转录组分析表明,E2F1在EBV潜伏期被转录激活,但在裂解重新激活期间显著受到抑制。虽然异位表达E2F1会抑制裂解复制,但敲低E2F1会显著加速这一过程。从机制上讲,我们发现E2F1与裂解反式激活因子BZLF1形成负转录反馈环,严格控制病毒裂解复制。此外,E2F1正向调节c-Myc的表达,并且它们共同在潜伏期抑制渗漏性BZLF1的表达。值得注意的是,c-Myc不影响E2F1的表达,BZLF1也不调节c-Myc的转录,这突出了一种独特的调控层次。总之,我们的研究结果表明,EBV通过精确调节E2F1的表达来严格控制潜伏到裂解的转换,将E2F1定位为细胞和病毒基因表达的关键调节因子。
Front Microbiol. 2024-12-5
Nucleic Acids Res. 2024-1-5
Biomed Pharmacother. 2023-8
Cancers (Basel). 2022-11-24
PLoS Pathog. 2022-10-20